All In Biotech

Drug Trial Radar · NCT03845712

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jul 5, 2019

Primary completion

Aug 26, 2026

Study completion Aug 26, 2026

Sponsor

Lead sponsor
UCB BIOSCIENCES, Inc.UCB
Sponsor type
Industry
First posted
Feb 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.

Conditions

  • Thymidine Kinase 2 Deficiency

Interventions

  • doxecitine and doxribtimineDrug

    Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From first administration of study drug until end of safety follow-up (up to approximately 7 years)
  2. Incidence of TEAEs leading to study drug withdrawalTime frame: From first administration of study drug until end of safety follow-up (up to approximately 7 years)

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Tk0102 1005

    New York, New York

  • Tk0102 4038

    Haifa, Israel

  • Tk0102 4039

    Holon, Israel

  • Tk0102 4037

    Nehariya, Israel

  • Tk0102 3102

    Barcelona, Spain

  • Tk0102 3121

    Esplugues de Llobregat, Spain

  • Tk0102 3031

    Madrid, Spain

  • Tk0102 3101

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.